AI选股记录
首页AI Top3 #3 概率 63%这个股票来自自动 AI 选股池。以后只要 CLI 写入新的 ticker，这里会自动生成个股页面，不需要手工补页面。
候选池相对强度最高。第二季度收入同比增长52%，检测服务收入增长61%，公司显著上调全年收入及调整后EBITDA指引；同时，移植监测产品的Medicare最终覆盖政策预计于8月30日生效，基本面催化仍在延续。
基本信息
成交结构
基于近 60 日量价数据观察资金强弱。
交易信号历史
按时间回看该股票被模型捕捉到的买点信号。
| 信号日期 | 模型来源 | 评分/强度 | 信号价格 | 止损价 | 止盈价 | 当前表现 | 操作结论 |
|---|---|---|---|---|---|---|---|
| 2026-08-13 | 动量强势 | +125.5% | $47.31 | $41.63 | $58.66 | +11.7% | 可买入 |
| 2026-08-12 | 动量强势 | +116.3% | $47.23 | $41.56 | $58.57 | +11.8% | 可买入 |
| 2026-08-11 | 动量强势 | +113.9% | $47.07 | $41.42 | $58.37 | +12.2% | 可买入 |
| 2026-08-10 | 动量强势 | +109.1% | $46.69 | $41.09 | $57.90 | +13.1% | 可买入 |
| 2026-08-07 | 动量强势 | +110.3% | $46.29 | $40.74 | $57.40 | +14.1% | 可买入 |
公司简介
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
